The Gene Synthesis Market has emerged as one of the most transformative segments within modern biotechnology, driven by rapid ...

The U.S. Food and Drug Administration (FDA) refused to consider Moderna’s application for a new flu vaccine using mRNA technology, the company announced Tuesday, a decision that could delay the ...

The Food and Drug Administration headquarters in Maryland. (Sara Silbiger/Getty Images) Moderna spent years and hundreds of millions of dollars developing a flu vaccine using the same technology that ...

The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday. The move is the latest sign that the FDA, under Health Secretary Robert F.

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice. The ...

Modern synthetic biology and AI represent both medicine’s greatest breakthrough and warfare’s most terrifying evolution. In this new landscape, where biological weapons can be designed faster than ...

An experimental drug custom-made to target the genetic mutations of individual tumors showed promise in treating aggressive skin cancer, according to new results from a clinical trial announced ...

mRNA molecule, illustration. [Kateryna Kon/Science Photo Library/Getty Images] Messenger RNA (mRNA) has already transformed medicine, most notably through COVID‑19 vaccines that taught cells to act as ...

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has outperformed standard seasonal flu shots by 34.5%. It's yet another sign that this ...

Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported. The Pfizer flu vaccine uses the same type of messenger RNA science that was used in the ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. Of 9,225 ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...